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ABSTRACT
Background: Psoriasis is a chronic
immune-mediated disease that affects 2–3% of
the world population. Ultraviolet B (UVB)
phototherapy is an effective treatment for
psoriasis compared to other systemic
treatments. Currently there is a lack of easily
accessible online patient educational material
regarding this form of treatment.
Objective: To present a freely available online
guide and video on UVB treatment that is
informative to patients and increases the
success and compliance of patients starting
this therapy.
Methods: The UVB treatment protocol used at
the University of California—San Francisco
Psoriasis and Skin Treatment Center as well as
available information from the literature was
reviewed to design a comprehensive guide for
patients receiving UVB treatment.
Results: We created a printable guide and video
resource that reviews the fundamentals of UV light,
UVB safety considerations, flow of treatment, side
effects, and post-phototherapy skin care.
Conclusion: This guide serves as a valuable
resource for patients preparing for UVB
phototherapy, the clinicians who treat them,
and trainees wishing to learn more about this
form of therapy.
Keywords: Patient education; Phototherapy;
Psoriasis; Ultraviolet B; UVB; Video guide
INTRODUCTION
Phototherapy, or light therapy, involves
regularly exposing the skin to specific
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wavelengths of ultraviolet (UV) light under
medical supervision to treat various skin
conditions. The UV light spectrum is divided
into UVC (200–280 nm), UVB (280–320 nm),
and UVA (320–400 nm). UVB is further
subdivided into broadband (280–320 nm) and
narrowband (311–313 nm) portions [1].
Dermatologists began utilizing broadband
UVB (BB–UVB) for the treatment of psoriasis
in the late 1970s. In the following two decades,
they discovered that narrowband UVB
(NB-UVB) was potentially safer and more
effective, with faster skin clearance and
longer-lasting remission. Furthermore, it is
thought that NB-UVB encompasses
‘‘therapeutic’’ wavelengths that are distinct
from ‘‘burning’’ wavelengths in the UVB
spectrum [2]. NB-UVB subsequently replaced
BB-UVB as a first-line treatment for psoriasis
[3–7].
Common indications for NB-UVB
phototherapy include psoriasis, atopic
dermatitis, and vitiligo [1, 8]. Although
BB-UVB is now rarely used for psoriasis, it can
be effectively used for atopic dermatitis and
generalized pruritus. Moreover, some patients
who respond inadequately to NB-UVB may
benefit from a trial of BB-UVB.
Typically, patients with moderate-to-severe
psoriasis require 20–36 sessions of NB-UVB
phototherapy at a frequency of three sessions
per week to see a significant improvement in
their skin [9]. Each phototherapy appointment
usually lasts about 15 min, although some
patients may require up to 30 min, if more
time preparing for phototherapy is needed. A
minimum of 24 h is required between each
session. Additionally, physician follow-up is
required every 3 months for the first year of
treatment and then every 6 months thereafter.
At the end of the initial phase of therapy,
clearance rates are often reported to be in the
60–70% range, which is comparable to many of
the systemic agents available for the treatment
of moderate-to-severe psoriasis today [4, 10, 11].
After skin clearing, the frequency of
phototherapy is gradually reduced to once
weekly for long-term maintenance.
Initial dosing of phototherapy at the
University of California–San Francisco (UCSF)
Psoriasis and Skin Treatment Center is based on
a patient’s Fitzpatrick skin type, for instance
with skin type I starting at 130 mJ and skin type
VI starting at 400 mJ. If a patient is on a
concomitant photosensitizing drug at the start
of treatment, the initial dose is shifted down
one level to that of the preceding Fitzpatrick
skin type. As treatment progresses, small
incremental increases in dose are introduced
as tolerated to minimize skin toxicity and total
UVB exposure. The treatment goal is to
maintain a mild amount of erythema for
optimal results [12].
If a patient does not receive UVB
phototherapy for a period of 12–20 days, the
dose is decreased by at least 25% to prevent skin
from burning. A 21- to 27-day break requires a
50% reduction in dose. Finally, 28 or more days
off requires the patient to start the regimen
again.
Patients are encouraged to consistently use
topical medications as prescribed in
conjunction with phototherapy to achieve the
best results. This may include topical
corticosteroids, topical vitamin D analogs, or
topical retinoids [13–16]. Patients taking
acitretin, an oral retinoid, may continue to do
so; however, it is recommended that the initial
phototherapy dose may be decreased by 25%.
Biologic agents can be successfully combined
with phototherapy for enhanced efficacy. Other
systemic agents such as cyclosporine and
methotrexate are not typically used in
conjunction with phototherapy [17] due to a
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possible increased risk of skin cancer or
phototoxicity, respectively [18].
Below, we will describe the safety
considerations, flow of treatment, appropriate
skin care, and possible side effects of UVB
phototherapy.
METHODS
We reviewed the UVB phototherapy treatment
protocol used at the UCSF Psoriasis and Skin
Treatment Center. We also performed a
PUBMED search using ‘‘ultraviolet B’’ or ‘‘UVB’’
AND ‘‘phototherapy’’ to identify relevant
articles to design a comprehensive guide for
patients receiving UVB treatment.
This article does not involve any new studies
of human or animal subjects performed by any
of the authors. All photos are printed with the
consent of the subject(s).
RESULTS AND DISCUSSION
Overview
Each UVB phototherapy session involves the
patient as well as a care team of nurses,
supporting staff, and/or doctors (Table 1). The
phototherapy is delivered in a light box with
adjustable energy settings, a fan, and a timer
that are all controlled by a nurse. Although the
light administration itself is often very brief
(ranging from several seconds to a few minutes),
much of the appointment consists of
before-and-after precautions taken to ensure
patient safety while maximizing treatment
efficacy. Therefore, each appointment
generally lasts about 15 min, although some
patients may require up to 30 min, if more time
preparing for light therapy is needed.
Safety Precautions
Patients must bring a list of all current
medications, including herbs and
supplements, to the first appointment for
review with the phototherapy nurse (Table 2;
Fig. 1). In general, patients should notify the
nurse of any medication changes as they arise.
For each session of phototherapy, patients must
have bare skin that is free of lotions and
perfumes or colognes, as these may make skin
more sensitive to light. Eye protection with
UVB-filtering goggles provided in the clinic is
required unless there are periorbital lesions
(skin involvement around the eyes) that may
benefit from UVB light. In that case, closing the
eyelids during irradiation will suffice, as it has
Table 1 Overview of ultraviolet B phototherapy
Typically requires 20–36 sessions
3 sessions per week
Appointments last between 15 and 30 min
Minimum 24-h interval between each session
Physician follow-up every 3 months for the first year
Physician follow-up every 6 months after the first year
Clearance rates range from 60 to 70%
Table 2 Safety precautions for ultraviolet B phototherapy
Disclosure of all current medications, herbs, and
supplements
Bare skin (no skin care products) prior to phototherapy
sessions
Eye protection with clean goggles or close the eyes (Fig. 1)
Face shielding with towel
Male genital coverage with cone or towel
Safe for use in pregnancy
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been shown that UV light does not penetrate
the eyelids [19]. A towel is also generally
wrapped around the face if the skin condition
is not present there. Finally, genital coverage is
required of all male patients unless an exception
has been approved by a physician. NB-UVB is
also safe for use in pregnancy [20, 21].
Flow of Treatment
At each session of phototherapy, the patient
checks in at the front desk and proceeds to
gather all necessary supplies, which include
clean goggles, a hospital gown, towels, and
genital coverage for men (Table 3; Fig. 2). The
phototherapy nurse asks the patient to state his/
her full name and date of birth to ensure safety.
The patient then changes into a hospital gown
in a dressing room. The nurse then examines
the patient’s skin thoroughly to assess skin
response from previous phototherapy
treatments, if applicable. This helps the nurse
determine if any phototherapy dose adjustment
will be required for the session. Next, the
patient is asked to step into the UVB box and
to assume a position that ensures maximal light
penetration to all affected areas. The nurse then
adjusts the light settings according to the
patient’s needs and the session is started. UVB
light is administered to the patient’s skin for
several seconds to minutes, depending on the
dose. In some cases, the nurse may cover the
patient’s face and/or trunk and give additional
doses to the arms and legs. This is because the
arms and legs can typically withstand higher
doses of light without burning, and higher
doses of light may be required to treat the
Fig. 1 UVB eye protection
Table 3 Flow of treatment for UVB phototherapy
Patient checks in at front desk 
↓
Patient gathers supplies (gown, towels, goggles, genital coveragea)
↓
Patient states full name and date of birth to nurse 
↓
Patient changes into gown and nurse examines patient’s skin (Fig. 2)
↓
Patient enters UVB box 
↓




Patient applies lotion to skin
UVB ultraviolet B
a Genital coverage may be required for male patients
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affected areas on the arms and legs compared to
the face and trunk. In some cases in which the
patient has psoriasis lesions on the lower legs,
the patient may be asked to stand on a step
stool to allow for a greater amount of light to
reach the lower legs. After treatment, the
patient steps out of the UVB box and returns
to the dressing room where the nurse offers to
apply lotion to hard-to-reach areas such as the
back, and gives the patient extra lotion to
moisturize the rest of his/her skin. Following
this, the patient can get dressed and the
treatment session is complete.
Post-Phototherapy Skin Care
It is important to minimize skin irritation
post-phototherapy (Table 4). When bathing,
patients should use a mild soap or skin
cleanser. Shortening shower times and
limiting showers to once per day is helpful. In
addition, water temperature should be warm at
most, but not hot. It is important for patients to
moisturize their skin very thoroughly at least
twice daily while receiving phototherapy. The
best time to moisturize is immediately after
bathing.
Side Effects
Although maintenance of a mild skin erythema
is desired for optimal results, burning should be
avoided (Table 5). Signs and symptoms of
burning post-phototherapy include
moderate-to-severe redness, tenderness, pain,
tightness, itching, and rarely blistering of skin.
Normally, if a burn is secondary to light
treatment, it will become noticeable 4–6 h
after the phototherapy session. If patients
experience any of the signs or symptoms of
burning, they should promptly apply a topical
steroid to the affected skin in an effort to lessen
and arrest the burn. Patients are also
encouraged to call their phototherapy clinic
for further assistance if needed.
Other possible side effects of phototherapy
include photoaging and tanning [12]. No
significant increased risk of skin cancer,
Fig. 2 Pre-phototherapy skin inspection
Table 4 Post-phototherapy skin care for ultraviolet B
phototherapy
Bathe with mild soap or cleanser
Shorten shower times
Limit to one shower per day
Use warm (not hot) water only
Moisturize skin twice dailya
a Best time to moisturize is immediately after bathing
Table 5 Side effects of UVB phototherapy
Side effecta Signs/symptoms
Burning Redness, tenderness, pain, tightness,
itching, and rarely blistering
Noticeable 4–6 h after treatment
Photoaging Coarseness, wrinkling, laxity, increased
fragility, mottled pigmentation,




a Skin cancer is not a side effect of UVB phototherapy
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including basal cell carcinoma, squamous cell
carcinoma, and melanoma, has been seen in
association with NB-UVB phototherapy
regardless of the patient’s skin type [7, 22–24].
CONCLUSIONS
UVB phototherapy is a safe and effective
treatment option for patients with psoriasis,
eczema, vitiligo, and other photo-responsive
disorders. The key to success with phototherapy
is consistency. To achieve optimal results,
patients must commit to at least 20 sessions of
treatment. With the appropriate safety and skin
care precautions taken, phototherapy can help
patients safely achieve rapid skin clearance and
long-lasting remission. We hope this guide will
be a valuable resource for patients preparing for
UVB phototherapy, the clinicians who treat
them, and trainees wishing to learn more about
this form of therapy.
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